PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients

Immunotherapy with immune-checkpoint inhibitors is a promising treatment method for locally advanced or advanced non-small cell lung cancer (NSCLC) patients. Monoclonal antibodies against programmed death 1 (PD-1) and against its ligand (PD-L1) are used in several indications. Nivolumab (anty-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) were approved in second line therapy in a wide group of NSCLC patients [1, 2]. While pembrolizumab (anti-PD-1 antibody), in monotherapy, could be used in first or second line treatment of NSCLC patients with PD-L1 expression on tumor cells.

Source: Cancer Genetics and Cytogenetics - June 6, 2019 Category: Genetics & Stem Cells Authors: Pawe ł Krawczyk, Anna Grenda, Kamila Wojas-Krawczyk, Marcin Nicoś, Tomasz Kucharczyk, Bożena Jarosz, Katarzyna Reszka, Juliusz Pankowski, Kinga Krukowska, Aleksandra Bożyk, Justyna Szumiło, Marek Sawicki, Tomasz Trojanowski, Janusz Milanowski Tags: Original Article Source Type: research